Sequoia China joins US-based $155m ArriVent Biopharma's Series B round

Sequoia China joins US-based $155m ArriVent Biopharma's Series B round

Photo by National Cancer Institute on Unsplash

28 March, 2023

Edited by: Padma Priya

ArriVent Biopharma general catalyst Sofinnova Investments

Printed by Unregistered user on Thu, 17 Jul 2025 01:52:47 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Venture Capital

Sequoia China, Tiger Global back $50m Series B round in HRtech startup NowCoder

Venture Capital

Monolith, led by ex-Sequoia China & Boyu partners, boasts nearly $800m in AUM

Read more from Greater China

Climate Tech & ESG

Chinese solar companies pull back from US as Trump cuts incentives

Policy & Regulations

China vows to regulate ‘irrational’ competition in EV industry